Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2

Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic leukemia. Extended analysis of RESONATE-2 was conducted to determine long-term efficacy and safety of ibrutinib in older patients with chronic lymphocytic leukemia. A total of 269 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Barr, Paul M., Robak, Tadeusz, Owen, Carolyn, Tedeschi, Alessandra, Bairey, Osnat, Bartlett, Nancy L., Burger, Jan A., Hillmen, Peter, Coutre, Steven, Devereux, Stephen, Grosicki, Sebastian, McCarthy, Helen, Li, Jianyong, Simpson, David, Offner, Fritz, Moreno, Carol, Zhou, Cathy, Styles, Lori, James, Danelle, Kipps, Thomas J., Ghia, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119145/
https://www.ncbi.nlm.nih.gov/pubmed/29880603
http://dx.doi.org/10.3324/haematol.2018.192328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119145/
https://www.ncbi.nlm.nih.gov/pubmed/29880603
http://dx.doi.org/10.3324/haematol.2018.192328

Ejemplares similares